Page last updated: 2024-08-21

pyrazines and temozolomide

pyrazines has been researched along with temozolomide in 16 studies

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (31.25)29.6817
2010's10 (62.50)24.3611
2020's1 (6.25)2.80

Authors

AuthorsStudies
Amiri, KI; Horton, LW; LaFleur, BJ; Richmond, A; Sosman, JA1
Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP1
Andrews, D; Curran, WJ; Dicker, AP; Kubicek, GJ; Machtay, M; Mallon, G; Myers, T; Ramirez, M; Werner-Wasik, M1
Schiff, D; van den Bent, MJ; Wen, PY1
Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y1
Blaskovits, FM; Carson, WE; Chan, AN; Grignol, VP; Guenterberg, KD; Lesinski, GB; Mundy, BL; Nuovo, GJ; Raig, ET; Young, GS; Zimmerer, JM1
Chen, CC; D'Andrea, A; Hu, L; Kesari, S; Kung, A; Ng, K; Nitta, M1
Bota, DA; Gong, X; Linskey, ME; Schwartz, PH1
Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P1
Befani, CD; Hatzidaki, E; Liakos, P; Papandreou, CN; Vlachostergios, PJ1
Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J1
Aleksic, T; Asher, R; Bridges, E; Gao, S; Kamdoum, WP; Li, JL; Macaulay, VM; Margison, GP; Middleton, MR; Pfister, SX; Ramcharan, R; Repapi, E; Tanner, J; Watson, AJ; Woodcock, M1
Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M1
Bindra, RS; Breslin, H; Burgenske, DM; Ganesa, S; Gilad, O; Jackson, CB; Jia, L; Kalathil, AN; Noorbakhsh, SI; Sarkaria, JN; Sundaram, RK1
Ang, BT; Chong, YK; Koh, LWH; Lim, SW; Ng, WH; Sandanaraj, E; Tan, MSY; Tan, NS; Tan, P; Tang, C1
Ang, BT; Cheng, HS; Chong, YK; Law, CLD; Low, ZYJ; Marvalim, C; Tan, NS; Tang, C; Zhu, P1

Reviews

1 review(s) available for pyrazines and temozolomide

ArticleYear
Neurological adverse effects caused by cytotoxic and targeted therapies.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration

2009

Trials

3 trial(s) available for pyrazines and temozolomide

ArticleYear
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
    International journal of radiation oncology, biology, physics, 2009, Jun-01, Volume: 74, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pyrazines; Radiotherapy; Temozolomide; Treatment Outcome

2009
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-01, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Temozolomide; Treatment Outcome

2010
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Fatigue; Female; Humans; Liver; Lymphopenia; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrazines; Temozolomide; Treatment Outcome; Young Adult

2012

Other Studies

12 other study(ies) available for pyrazines and temozolomide

ArticleYear
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
    Cancer research, 2004, Jul-15, Volume: 64, Issue:14

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Pyrazines; Temozolomide

2004
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
    Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles

2008
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Interferons; Interleukins; Janus Kinase 1; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Signal Transduction; Skin Neoplasms; STAT Transcription Factors; Temozolomide

2010
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
    Clinical neurosurgery, 2009, Volume: 56

    Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Glioblastoma; Humans; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RNA Interference; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured

2009
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
    Neurology, 2011, Mar-29, Volume: 76, Issue:13

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide

2011
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.
    Investigational new drugs, 2013, Volume: 31, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitogen-Activated Protein Kinases; NF-kappa B; O(6)-Methylguanine-DNA Methyltransferase; Proto-Oncogene Proteins c-akt; Pyrazines; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53

2013
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Journal of neurosurgery, 2013, Volume: 119, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2013
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
    Oncotarget, 2015, Nov-24, Volume: 6, Issue:37

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Breaks, Double-Stranded; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Melanoma; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Pyrazines; Receptor, IGF Type 1; Survival Analysis; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2015
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
    Nature communications, 2015, Nov-25, Volume: 6

    Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway

2015
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
    Cancer research, 2019, 09-01, Volume: 79, Issue:17

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; DNA Breaks, Double-Stranded; DNA Damage; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; Female; Humans; Isoxazoles; Mice, Nude; Pyrazines; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2019
A STAT3-based gene signature stratifies glioma patients for targeted therapy.
    Nature communications, 2019, 08-09, Volume: 10, Issue:1

    Topics: Animals; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genetic Predisposition to Disease; Glioblastoma; Humans; Imidazoles; Insulin-Like Growth Factor Binding Protein 2; Mice; Pyrazines; Pyrazoles; Pyrimidines; Receptor, IGF Type 1; STAT3 Transcription Factor; Temozolomide; Xenograft Model Antitumor Assays

2019
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.
    Theranostics, 2021, Volume: 11, Issue:11

    Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Hypoxia; Male; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazines; Pyrrolidinones; Quinolines; Signal Transduction; Temozolomide; Transcriptome; Triazoles

2021